Mesalamine
Ulcerative Colitis
ShireSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
13 Active assets in the Ulcerative Colitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxygen Jay C. Buckey Jr. | Phase 4 | BB |
Mmx Mesalamine/Mesalazine Shire | Phase 3 | B |
Hextend Corewell Health West | Phase 3 | B |
Nivolumab Diwakar Davar | Phase 2 | B |
Tirzepatide Eli Lilly and Company | Phase 3 | B |
View all 30 →
Same molecule, other indications
Mesalamine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →